Loading
TQB3454 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for biliary tract cancer, aimed at IDH1 / IDH2.
TQB3454 is a small-molecule drug developed by Chia Tai Tianqing Pharmaceutical. Its target is IDH1 / IDH2 (the sponsor names IDH1 (mutant)). The sponsor states: Selective inhibitor of mutant IDH1 enzyme, given as an oral tablet, being tested against placebo in advanced biliary tract cancer patients with IDH1 mutations. ClinicalTrials.gov describes the intervention as: TQB3454 is a selective IDH1 mutant enzyme inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05987358 (A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma), in biliary tract cancer. The largest, NCT05987358, plans to enrol 165 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Selective inhibitor of mutant IDH1 enzyme, given as an oral tablet, being tested against placebo in advanced biliary tract cancer patients with IDH1 mutations. Connects to IDH1 / IDH2.
1.TQB3454 slips into a pocket on IDH1 / IDH2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TQB3454" OR ABSTRACT:"TQB3454") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TQB3454, not a curated reading list.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.